> Baltimore-based stem cell therapeutic company Osiris Therapeutics announced an IPO at 3.5 million shares for about $11 to $13 each. Report [1]
> Chutes & Ladders: Ann, Arbor, MI-based Aastrom Biosciences has named George W. Dunbar CEO and president. Release [2]
> Melbourne-based CSL Limited will acquire biotech Zenyth Therapeutics for about $108 million. Release [3]
> Amgen is initiating a 3,800-person study of Sensipar/Mimpara for kidney disease. Report [4]
And Finally... The Senate will continue to debate three stem cell bills which President Bush has pledged to veto if passed. Article [5] (WSJ sub. req.)
Links:
[1] http://today.reuters.com/investing/financeArticle.aspx?type=governmentFilingsNews&storyID=2006-07-17T132309Z_01_N17378972_RTRIDST_0_HEALTH-OSIRIS-IPO-URGENT.XML
[2] http://biz.yahoo.com/ap/060717/aastrom_biosciences_ceo.html?.v=1
[3] http://www.pipelinereview.com/joomla/content/view/5204/282/
[4] http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/306453/
[5] http://online.wsj.com/article/SB115309562445708235.html?mod=health_home_stories